Arena’s Real Issue: Drugs Vs. Gym & Behavior Modification (ARNA)

By Douglas A. McIntyre Updated Apr 27, 4:32PM EDT · Published Mar 30, 8:36AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

burning-money-pic40 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is getting shelled this morning. The company released “positive study data” this morning on trials for its obesity treatment Lorcaserin. But the real issue around the results is that it looks like the Wall Street answer is just “That’s it?”….

Arena’s positive top-line results from its behavioral modification and Lorcaserin for overweight and obesity management is the first of two pivotal trials evaluating the safety and efficacy for weight loss and weight management. The company noted that statistical significance was achieved on all three of the co-primary endpoints versus placebo. The endpoints were the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months.

The study showed that 47.5% of Lorcaserin patients lost greater than or equal to 5% of their body weight from the baseline, compared to 20.3% in the placebo group.

Average weight loss of 5.8% of body weight, or 12.7 pounds, was achieved in the Lorcaserin group, compared to 2.2% of body weight, or 4.7 pounds, in the placebo group.

The study said 22.6% of Lorcaserin patients lost greater than or equal to 10% of their body weight from the baseline, compared to 7.7% in the placebo group.

There is just one problem with these results in the “That’s it?” thesis. Going to a weight management seminar even once per month and using an exercise regimen at a gym should be able to do better than this. Unless someone is too fat to exercise or too out of shape to exercise, then there are no real side effects compared to any drug.

Shares are getting hit by 30% at $3.17 right before the open. The 52-week range is $2.70 to $7.42.

In the world of obesity treatment via drugs, the world is looking for that major weight-loss pill rather than an incremental boost from a pill. Again, the gym and a once a month class could produce better results… assuming the person wants to lose weight and is willing to engage in behavior modification.

JON C. OGG
March 30, 2009

About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.